BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 16215614)

  • 1. [Genetic variation-- important for the clinical effect of opioids?].
    Klepstad P; Dale O; Borchgrevink PC; Kaasa S; Skorpen F
    Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2655-8. PubMed ID: 16215614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variability and clinical efficacy of morphine.
    Klepstad P; Dale O; Skorpen F; Borchgrevink PC; Kaasa S
    Acta Anaesthesiol Scand; 2005 Aug; 49(7):902-8. PubMed ID: 16045647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Genetic polymorphisms and human sensitivity to pain and opioids].
    Nishizawa D; Nagashima M; Satoh Y; Tagami M; Ikeda K
    Masui; 2009 Sep; 58(9):1093-101. PubMed ID: 19764431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of opioids.
    Somogyi AA; Barratt DT; Coller JK
    Clin Pharmacol Ther; 2007 Mar; 81(3):429-44. PubMed ID: 17339873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects.
    Kolesnikov Y; Gabovits B; Levin A; Voiko E; Veske A
    Anesth Analg; 2011 Feb; 112(2):448-53. PubMed ID: 21127283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in interpreting joined allelic combinations of OPRM1 and COMT genes.
    Landau R; Ortner C; Carvalho B
    Anesth Analg; 2011 Aug; 113(2):432. PubMed ID: 21788333
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacogenetics of morphine: Potential implications in sickle cell disease.
    Darbari DS; Minniti CP; Rana S; van den Anker J
    Am J Hematol; 2008 Mar; 83(3):233-6. PubMed ID: 17722074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Influences of OPRM1, OPRD1 and COMT on Morphine Analgesia in a Multi-Modal, Multi-Tissue Human Experimental Pain Model.
    Nielsen LM; Christrup LL; Sato H; Drewes AM; Olesen AE
    Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):6-12. PubMed ID: 28084056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Side effects of opioid and gene variants].
    Sora I; Komatsu H; Igari M; Ide S; Ikeda K; Shimoyama N
    Masui; 2009 Sep; 58(9):1109-11. PubMed ID: 19764433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of genetic factors on opioid action.
    Kosarac B; Fox AA; Collard CD
    Curr Opin Anaesthesiol; 2009 Aug; 22(4):476-82. PubMed ID: 19502975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects.
    Ross JR; Riley J; Taegetmeyer AB; Sato H; Gretton S; du Bois RM; Welsh KI
    Cancer; 2008 Mar; 112(6):1390-403. PubMed ID: 18257092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic factors in pain and its treatment.
    Stamer UM; Stüber F
    Curr Opin Anaesthesiol; 2007 Oct; 20(5):478-84. PubMed ID: 17873601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain.
    De Gregori M; Garbin G; De Gregori S; Minella CE; Bugada D; Lisa A; Govoni S; Regazzi M; Allegri M; Ranzani GN
    Eur J Clin Pharmacol; 2013 Sep; 69(9):1651-8. PubMed ID: 23686330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers.
    Lötsch J; Geisslinger G
    Pharmacogenomics J; 2006; 6(3):200-10. PubMed ID: 16415919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene.
    Reyes-Gibby CC; Shete S; Rakvåg T; Bhat SV; Skorpen F; Bruera E; Kaasa S; Klepstad P
    Pain; 2007 Jul; 130(1-2):25-30. PubMed ID: 17156920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics in pain management: the clinical need.
    Webster LR
    Clin Lab Med; 2008 Dec; 28(4):569-79. PubMed ID: 19059063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can heterogeneity of chronic sickle-cell disease pain be explained by genomics? A literature review.
    Adegbola MA
    Biol Res Nurs; 2009 Jul; 11(1):81-97. PubMed ID: 19487302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics in palliative care.
    Kleine-Brueggeney M; Musshoff F; Stuber F; Stamer UM
    Forensic Sci Int; 2010 Dec; 203(1-3):63-70. PubMed ID: 20709477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of opioid pharmacogenetics.
    Argoff CE
    Clin J Pain; 2010 Jan; 26 Suppl 10():S16-20. PubMed ID: 20026961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Environmental and genetic factors associated with morphine response in the postoperative period.
    Coulbault L; Beaussier M; Verstuyft C; Weickmans H; Dubert L; Trégouet D; Descot C; Parc Y; Lienhart A; Jaillon P; Becquemont L
    Clin Pharmacol Ther; 2006 Apr; 79(4):316-24. PubMed ID: 16580900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.